Agile Therapeutics Reports Second Quarter 2021 Financial Results
26 juil. 2021 16h05 HE
|
Agile Therapeutics, Inc.
Total Prescriptions (TRx) Grew 171% in Second Quarter Prescribers, New Prescriptions and Refill Rates Continue to Grow in Second Quarter Company Continues to Progress on Expanding Access...
Agile Therapeutics Announces Presentation of Safety and Efficacy Data of Twirla® (Levonorgestrel and Ethinyl Estradiol) Transdermal System in Women of Differing BMI Categories at ACOG Annual Meeting
30 avr. 2021 11h01 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial...
CORRECTING AND REPLACING -- Agile Therapeutics
20 avr. 2021 10h56 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by Agile Therapeutics, Inc. (Nasdaq: AGRX), please note the headline should read "Agile Therapeutics to Report...
Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020
20 avr. 2021 09h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report first quarter 2021 financial results after...
Abstract on AG200-15 (Twirla®) Accepted for Presentation at the APhA 2018 Annual Meeting & Exposition
14 mars 2018 07h45 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 14, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company today announced that an abstract related to the Phase 3 SECURE study for...
Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
12 mars 2018 16h15 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 12, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, today reported financial results for the three months and year ended...
Agile Therapeutics Reports Third Quarter 2017 Financial Results
06 nov. 2017 16h20 HE
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations into Q2 2018 Prescription Drug User Fee Act (PDUFA) Goal Date for Twirla® is December 26, 2017 PRINCETON, N.J., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Agile...
Agile Therapeutics Inc. Hosts First Analyst Day Focused on Previewing its Corporate Vision and Commercial Strategy
10 oct. 2017 18h38 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s healthcare company, today hosted the Company’s first analyst day in New York City to showcase its...
Agile Therapeutics to Host First Analyst Day on October 10, 2017
02 oct. 2017 07h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the Company will host its first Analyst Day on Tuesday,...
Agile Therapeutics to Present Additional Phase 3 Data at the North American Forum on Family Planning Annual Meeting
28 sept. 2017 07h45 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that an abstract based on the Phase 3 SECURE trial of its...